FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileState Street SPDR S&P Biotech ETF
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
XBI
State Street SPDR S&P Biotech ETF Stock AnalysisComprehensive stock analysis for State Street SPDR S&P Biotech ETF (XBI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisXBI
XBI
State Street SPDR S&P Biotech ETF
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
XBI
  1. Home
  2. Stocks
  3. State Street SPDR S&P Biotech ETF

State Street SPDR S&P Biotech ETF

🇺🇸XBI•AMEX

State Street SPDR S&P Biotech ETF

🇺🇸XBI•AMEX
Market cap
$7.63B
Sentiment

Your view on XBI

Mkt Cap
$7.63B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About State Street SPDR S&P Biotech ETF

Industry
Asset Management
Sector
Financial Services
CEO
Not available
Headquarters
Boston, MA, US
Industry
Asset Management
Sector
Financial Services
CEO
Not available
Headquarters
Boston, MA, US
Description

The State Street SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index")Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: BiotechnologySeeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocksAllows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for State Street SPDR S&P Biotech ETF from FRC's valuation model, read against the market price. XBI last traded at $145.88; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for State Street SPDR S&P Biotech ETF. Starting points for State Street SPDR S&P Biotech ETF: beta 1.10 — an Asset Management name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF paid $0.57 per share over the last year — a 0.4% yield at the current $145.88 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for State Street SPDR S&P Biotech ETF. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Hold1 rating
  • Strong Buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong Sell0

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold XBI20 companies · 7 funds
Compare XBI with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • AIQGlobal X - Artificial Intelligence & Technology ETFAsset Management - Global$9.1B
  • BBINJPMorgan BetaBuilders International Equity ETFAsset Management$6.7B
  • BBUSJPMorgan BetaBuilders U.S. Equity ETFAsset Management$8.9B
  • EWZiShares MSCI Brazil ETFAsset Management$6.2B
  • FDLFirst Trust Morningstar Dividend Leaders Index FundAsset Management - Income$8.6B
  • IDViShares International Select Dividend ETFAsset Management - Income$8.1B
  • KBWBInvesco KBW Bank ETFAsset Management$5.0B
  • TCAFT. Rowe Price Capital Appreciation Equity ETFAsset Management$9.0B

More Asset Management companies

  • CCGDFChina Cinda Asset Management Co., Ltd.OTC$5.1B
  • CCVLCrown Cap Ventures Ltd.OTC$521
  • CEVIFChina Everbright LimitedOTC$2.1B
  • CEVIYChina Everbright LimitedOTC$910M
  • CFNBCalifornia First Leasing CorporationOTC$255M
  • CGThe Carlyle Group Inc.NASDAQ$14.1B
  • CGABLThe Carlyle Group Inc. 4.625% Subordinated Notes due 2061NASDAQ$5.1B
  • CGBDCarlyle Secured Lending, Inc.NASDAQ$754M
  • CHAMChampion Investments, Inc.OTC$7,548
  • CHMJFWaverunner Capital Inc.OTC$694,618
  • CICCCION Investment Corp. 7.5 % Notes 2026-31.03.31NYSE$419M
  • CIN.AXCarlton Investments LimitedASX

ETFs holding State Street SPDR S&P Biotech ETF

% of the fund

  • BDYNiShares Dynamic Equity Active ETF$3.0B in assets0.36%
  • TIHThe Investment House ETF$653M in assets0.47%
  • XNAVFundX Aggressive ETF$28M in assets3.63%
  • GEQCambria Global EW 2 ETF$203M in assets0.43%
  • WLTGWealthTrust DBS Long Term Growth ETF$77M in assets0.95%
  • HFEQUnlimited HFEQ Equity Long/Short ETF$12M in assets2.20%
  • HFNDUnlimited HFND Multi-Strategy Return Tracker ETF$36M in assets0.56%

Largest holders first, then the funds most concentrated in XBI.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold State Street SPDR S&P Biotech ETF, and how their positions are changing. At a $7.63B market value, institutional positions materially move State Street SPDR S&P Biotech ETF's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF is a $7.63B Financial Services company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming State Street SPDR S&P Biotech ETF. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for State Street SPDR S&P Biotech ETF. Coverage tracks State Street SPDR S&P Biotech ETF within Asset Management (Financial Services). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of State Street SPDR S&P Biotech ETF.

XBI Analysis
Weak
Past5
Growth1
Health1
Profit1
Value1

News

Latest Market News